A Multivalent Vaccine Containing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae Antigens Elicits Strong Immune Responses and Promising Protection in Pigs

ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access

A Multivalent Vaccine Containing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae Antigens Elicits Strong Immune Responses and Promising Protection in Pigs

Hoai Thu Dao^1,5, Woo-Sung Shin², Van Tan Do^1,5, Quang Lam Truong³, Jong-Young Choi^1,4 and Tae-Wook Hahn^1,2

¹College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon 24341, Korea.

²Innovac Co., Kangwon National University, 1 Kangwondaehak-gil, Chuncheon 24341, Korea.

³Key Laboratory of Veterinary Biotechnology, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi, Vietnam.

⁴Dodam Veterinary Clinics, Seoul 04716, Korea.

⁵Institute of Veterinary Research and Development of Central Vietnam, Vietnam.

J Pure Appl Microbiol. 2021;15(1):164-174 | Article Number: 6438

https://doi.org/10.22207/JPAM.15.1.11 | © The Author(s). 2021

Received: 29/05/2020 | Accepted: 04/01/2021 | Published: 02/02/2021

Read the full text ❯

Abstract

Actinobacillus pleuropneumoniae (App) and Mycoplasma hyopneumoniae (Mhp) cause porcine pleuropneumonia and mycoplasmal pneumonia, respectively, and have serious impacts on the swine industry because they retard the growth of pigs. To protect pigs against these diseases, we have developed a multivalent vaccine consisting of App bacterins, APP RTX toxins (Apx toxins), and Mhp bacterin and adhesin protein. This vaccine induced the production of higher levels of antibodies against App and Mhp than the commercial vaccine (Nisseiken Swine APM Inactivated Vaccine). Furthermore, the vaccine efficiently protected pigs against virulent App challenge, showing promise as an efficient vaccine for the prevention of two important respiratory diseases, porcine pleuropneumonia and mycoplasmal pneumonia.

Keywords

Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, multivalent vaccine, immune responses, protection efficacy

Download PDF

Article Metrics

Article View: 923

JPAM.15.1.11 (1566 downloads)

Share This Article

© The Author(s) 2021. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.